Key facts
- It has raised $50K; the latest was Accelerator/Incubator in Jun 2025.
- Notable investors include PharmStars, Character (VC), Next (Consulting Services).
- Comend has filed 1 Form D with the SEC, most recently Mar 2025 ($50K sold to 1 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Comend
- ·The full record, as it builds
Funding rounds
No funding rounds for Comend are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Comend
Developer of search tools designed to develop treatments in the long tail of disorders. The company's tool creates the building blocks by finding patients and funding research for new drug programs in rare diseases, enabling patient groups to drive research in disease treatments as per specific needs.
- Sector
- Healthcare
- HQ
- Mississauga, Canada
- Founded
- 2023
- Employees
- 10
- Website
- comend.io/
- Ownership
- Privately Held (backing)
Comend doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Comend shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Comend in its N-PORT filings yet. We sweep new filings monthly.